-
OICR partners with Janssen to identify prostate cancer biomarkers
TORONTO | The Ontario Institute for Cancer Research is collaborating with pharmaceutical company Janssen to find and test new biomarkers to identify patients with hormone-resistant prostate cancer at high risk for disease progression and biomarkers of response to therapy.